4.3 Article

Regional Disparity in First-in-Class Anticancer Drug Development in the US, EU, and Japan

期刊

BIOLOGICAL & PHARMACEUTICAL BULLETIN
卷 46, 期 5, 页码 700-706

出版社

PHARMACEUTICAL SOC JAPAN

关键词

first -in -class; anticancer; regulatory policy; drug development; drug lag

向作者/读者索取更多资源

A cancer diagnosis is devastating and the demand for innovative anticancer drugs is high worldwide. This study focused on the development of first-in-class (FIC) anticancer drugs in the US, EU, and Japan. The approval time for FIC anticancer drugs was significantly longer in Japan compared to the US and EU. There were substantial lags in submission and approval between Japan and the US/EU, highlighting the need for improved international cooperation to reduce these drug lags.
A cancer diagnosis is devastating for both patients and their caregivers. With high morbidity and mortality, cancer is a serious disease area with unmet medical needs. Thus, innovative anticancer drugs are in high demand worldwide but are unequally available. Our study focused on first-in-class (FIC) anticancer drugs and investigated their actual development situation in the United States (US), European Union (EU), and Japan over the last two decades to obtain fundamental information for understanding how the aforementioned demands are met, especially to eliminate drug lags among regions. We identified FIC anticancer drugs using pharmacological classes for the Japanese drug pricing system. Most FIC anticancer drugs were first approved in the US. The median approval time for anticancer drugs in new pharmacological classes during the last two decades in Japan (5072 d) was significantly different (p = 0.043) from that in the US (4253 d), though it was not significantly different from that in the EU (4655 d). Submission and approval lags between the US and Japan were more than 2.1 years, and those between the EU and Japan were more than 1.2 years. However, those between the US and the EU were less than 0.8 years. The development rate of FIC anticancer drugs in Japan is slower than in other regions. Even among developed countries, FIC anticancer drug lags exist. Considering the high impact of FIC anticancer drugs on society worldwide, we should work together to reduce drug lag among regions using an improved international cooperative framework.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据